Seth Christensen's friends and family are joining together to raise money so that he can join an important ALS clinical trial in Utah.
On August 24, 2010 Seth was diagnosed with ALS, a rare syndrome characterized by the breakdown of the motor neuron system. He was told at the time of his diagnosis that the prognosis was terminal and that there was no known treatment for ALS. Since that day, he and Amy have sought to participate in an number of clinical trials including moving their family to Israel to pursue a leading trial earlier this summer. After any further admission to the Israeli trial was closed, Seth and Amy returned to the United States and turned their attention to a promising trial based at Emory University in Atlanta Georgia. In a 2012 stem cell trial with ALS patients at Emory University, one patient demonstrated clear improvement, a finding that is unheard of in patients with ALS. This observation drew attention to the novel immunosuppression regimen used in this trial and the possible existence of a subset of patients with an immune-responsive ALS subtype.
The FDA has subsequently approved a formal trial of this immunosuppressive regimen. That trial is full and is expected to begin shortly. Because Seth's own labs show autoimmune irregularities (not known to be linked to ALS), researchers at the University of Utah have gained approval, but not funding, to treat Seth according to the Emory protocol using this same immunosuppression regimen on a trial basis. Seth begins this trial in a few days. The fundraising will allow for the treatment and travel during the 6 month trial period. Thank you for your support and generosity in helping Seth and Amy fight this terrible disease.